Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215403 · ClinicalTrials.gov registry record · Phase 2
Prescriptive Infusion Algorithm (PIA)
A Phase 2 study, sponsored by AskBio.
- Not yet
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT07215403: Clinical Trial Phase 2 study, sponsored by AskBio.
NCT07215403 is a Phase 2 study that has not yet begun recruiting, run by AskBio. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215403, a Phase 2 study, has not yet begun recruiting, sponsored by AskBio.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal surgical approach) can consistently deliver AB-1005 to the putamen using MRI monitoring. Technical (Stage 1) To test if the new delivery method (PIA-based infusion) can consistently deliver AB-1005 to the putamen using brain imaging by MRI. Technical (Stage 2) To confirm the new delivery method works without brain imaging by MRI, using standard operating room tools including brain imaging by CT. Safety (Stage 1 and 2) To assess the safety and tolerability of the new delivery method for AB-1005 up to 6 months after surgery
Primary Outcome
Investigate the use of PIA-based infusion for consistent intraputaminal administration of AB-1005 via CED under iMRI monitoring
Interventions
- PROCEDURE Prescriptive Infusion Algorithm
- DRUG AB-1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
What is known before NCT07215403 opens enrollment
NCT07215403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 2 interventions - of which Prescriptive Infusion Algorithm is the first listed.
NCT07215403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07215403 about?
NCT07215403 is a clinical study titled "Prescriptive Infusion Algorithm (PIA)". This study is being done to test a new way of delivering AB-1005 into the brain. The goal is to make the procedure easier and quicker to perform, while providing similar amounts of drug to the part of the brain that needs treatment. Technical (Stage 0) To test if the new delivery method (prefrontal...
What is the current status of trial NCT07215403?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2026-07-15. Estimated completion is 2028-03-01.
What interventions are being tested in trial NCT07215403?
The interventions under investigation include: Prescriptive Infusion Algorithm (PROCEDURE), AB-1005 (DRUG).
Who is sponsoring clinical trial NCT07215403?
This trial is sponsored by AskBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07215403's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI